市場調査レポート

世界の膀胱癌治療薬市場

Bladder Cancer Therapeutics

発行 Global Industry Analysts, Inc. 商品コード 138784
出版日 ページ情報 英文 580 Pages
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
世界の膀胱癌治療薬市場 Bladder Cancer Therapeutics
出版日: 2010年10月01日 ページ情報: 英文 580 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

当レポートでは、世界の膀胱癌治療薬市場について分析し、膀胱癌の概要と治療法、認可済みおよび開発中の薬剤動向とともに、各国市場別の動向、参入企業のプロファイルを交え、概略下記の構成でお届けいたします。

第1章 イントロダクション、方法論、製品定義

第2章 エグゼクティブサマリー

  • 業界概要
    • イントロダクション
    • 膀胱癌は警告レベルに拡大
    • 膀胱癌統計
    • 再発動向
    • 既存の薬物療法
    • 膀胱癌は新たな治療薬を求めている
    • 将来動向
    • 新薬の登録プロセス
    • 競合環境
  • 市場動向と課題
    • 喫煙と発癌性物質
    • 女性よりも男性のリスクが高い
    • 高齢者の新たな治療薬
    • 膀胱癌治療のためのレーザー 他
  • 膀胱癌治療
    • 非侵襲性治療
    • 侵襲性治療
    • 転移性膀胱癌
    • その他の治療法
  • 主な膀胱癌治療薬
    • 概要
    • 認可済み薬剤
    • 後期段階
    • その他
  • 膀胱癌の概要
    • 癌診断
    • 癌の治療戦略
    • ヒトの膀胱
    • 膀胱癌の分類
    • 膀胱癌の種類
    • 主なリスクファクター
    • 症状と診断 他
  • 研究開発
  • FDA認可と申請
  • 近年の業界活動
  • 参入企業
  • 世界市場見通

第3章 市場

  • 米国
  • 日本
  • 欧州
  • その他の地域

競合プロファイル:62社(事業部/子会社含め:67社)

目次
Product Code: MCP-6020

Abstract

This report analyzes the worldwide markets for Bladder Cancer Therapeutics in US$ Million. The report provides separate comprehensive analytics for US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A six-year historic analysis is also provided for these markets. The report profiles 62 companies including many key and niche players such as Affitech A/S, Allergan, Inc., Allos Therapeutics, Inc., Astellas Pharma, Inc., Astrazeneca Plc, AVI BioPharma, Inc., BioCancell Therapeutics, Inc., Bioniche Life Sciences, Inc., Bristol-Myers Squibb Company, Celldex Therapeutics, Inc., Cytavis BioPharma GMBH, Eli Lilly and Company, Endo Pharmaceuticals Holdings, Inc., ENKAM Pharmaceuticals A/S, F. Hoffmann-La Roche Ltd., Halozyme Therapeutics, Inc., Laboratoires Pierre Fabre SA, NatImmune A/S, Oncogenex Pharmaceuticals, Inc., OncoTherapy Science, Inc., Sanofi-Aventis, Spectrum Pharmaceuticals, Inc., Telormedix SA, and Viventia Biotechnologies, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Introduction
  • Bladder Cancer Growing at an Alarming Rate
  • Bladder Cancer Statistics
    • Table 1: Worldwide Incidence of Bladder Cancer bySelect Countries/Region (2003 & 2013): US, Europe,and Japan (In ' 000s) (includes correspondingGraph/Chart)
    • Table 2: Worldwide Incidence and MortalityRates of Select Cancer Types in Males: 2007(includes corresponding Graph/Chart)
    • Table 3: Incidence and Mortality Rates of Select CancerTypes in Industrialized Countries: 2007(includes corresponding Graph/Chart)
    • Table 4: Incidence and Mortality Rates of Select CancerTypes in Developing Markets: 2007 (includescorresponding Graph/Chart)
  • Recurrent Nature: A Major Cause of Concern
  • Bladder Cancer: The Most Costly Cancer To Treat
  • Generics Characterize Bladder Cancer Market
  • Existing Drug Therapies Lack in Assuring Long Term Survival Rate
    • Approved Intravesical Agents for Bladder Cancer
  • Bladder Cancer Demands New Therapeutics to Fill the Void
    • Table 5: Number of Pipeline Drugs by Select CancerTypes (includes corresponding Graph/Chart)
  • What the Future Holds?
    • Table 6: World Market for Bladder Cancer Therapeutics (2008): Percentage Share Breakdown of Total Numberof Drugs by Development Stage (includescorresponding Graph/Chart)
    • Emerging Therapeutic Options for SuperficialBladder Cancer
      • Table 7: EOquin Penetration Rate in the US forthe Years 2011 through 2015 (includescorresponding Graph/Chart)
      • Table 8: US Market for EOquin: Annual RevenueProjections for the Years 2011 through 2015 inUS$ Million (includes corresponding Graph/Chart)
  • Registration Process for New Drugs: A Review
  • Competitive Landscape
    • Leading Therapeutics in Global Bladder Cancer Market
    • Select Companies Involved in Late-Stage Bladder
      • Cancer Clinical Trials
    • Select Companies Involved in Phase-II Clinical Trials
    • Select Companies Involved in Phase-I Clinical Trials
    • Select Companies Involved in Pre-clinical Stage
  • Current and Future Analysis

2. MAJOR TRENDS & ISSUES

  • Cigarette Smoking and Carcinogenic Substances: The Major Culprits
  • Men at High Risk than Women
  • New Therapeutics for Elderly Population: Need of the Hour
  • Lasers for Bladder Cancer Treatment: An Evolving Approach
  • Photodynamic Therapy (PDT) Holds Potential
  • SonoPhoto Dynamic Therapy - A New Treatment for Non-Invasive Bladder Cancer

3. BLADDER CANCER TREATMENT

  • Non-Invasive (Superficial) Bladder Cancer Treatment
    • Treatment Options and Potential Side Effects
    • Surgery
    • Immunotherapy
    • Intravesical Chemotherapy
  • Invasive Bladder Cancer Treatment
    • Treatment Options, and Potential Side Effects
    • Surgery
      • Cystectomy
        • Partial Cystectomy - A Part of Bladder is Removed
        • Radical Cystectomy - Entire Bladder is Removed
          • Side Effects of Removing the Bladder
          • What' s the Solution if the Bladder Is Removed?
      • Reconstructive Surgery
        • Continent Urinary Diversion or Ileal Loop Diversion
        • Neobladder
    • Radiotherapy
    • Systemic Chemotherapy
  • Metastatic Bladder Cancer
    • Palliative Treatment
  • Other Treatment Options
    • Targeted Therapy
    • Gene Therapy
    • Chemoprevention
    • Chemoradiotherapy
    • Photodynamic Therapy (PDT)
    • Complementary Therapies

4. MAJOR BLADDER CANCER DRUGS

  • A Quick Market Primer
    • Leading Bladder Cancer Therapeutics
    • Select Bladder Cancer Therapeutics in Pipeline: 2009
  • Approved Bladder Cancer Drugs
    • Thiotepa
    • Adriamycin (Doxorubican hydrochloride)
    • Methotrexate
    • Vinblastine
    • Epirubicin
    • Mitomycin C
    • Mitoxzantrone
    • Oxaliplatin
    • IL2 (Aldesleukin) and Interferon into the Bladder
    • Keyhole Limpet Haemocyanin (KLH)
    • Platinol-AQ (Cisplatin)
    • Gemzar (Gemcitabine)
    • OncoTICE/TICE BCG
    • PACIS™ BCG
    • Valstar (valrubicin)
  • Late-Stage Pipeline Drugs
    • EOquin (Apaziquone)
    • Urocidin (MCC)
    • Larotaxel (XRP-9881)
    • Javlor® (Vinflunine)
    • 4-HPR (Fenretinide)
  • Pipeline Analysis of Other Potential Drugs
    • BEXIDEM [On-Hold]
    • BC-819 [Phase IIb]
    • CDX-1307 [Phase I]
    • Chemophase® [Phase I/IIa]
    • PDX [Pralatrexate] [Phase II]
    • OGX-427 [Phase I]
    • OGX-011 [Phase II]
    • Celebrex (Celecoxib) [Phase IIb/III]
    • TMX-101 [Pre-Clinical Stage]
    • AGSPSCA [Phase Ib]
    • Iressa with Gemzar [Phase II]
    • MDR09521[Development Stage]
    • siRNA ALPHAGEN [Development Stage]

5. AN OVERVIEW OF BLADDER CANCER

  • Cancer - An Insight
    • Factors Causing Cancer Ranked in Order of Impact
  • Cancer Diagnosis
  • Treatment Strategies for Cancer
    • Progressing R&D Efforts to Innovate Drug Delivery for Cancer Treatment
  • The Human Bladder: A Urine Storing Organ
  • Bladder Cancer - Introduction
  • Classification of Bladder Cancer
    • Non-Invasive Cancer
    • Invasive Cancer
  • Types of Bladder Cancer
    • Transitional Cell Carcinoma/Urothelial Carcinoma
    • Squamous Cell Carcinoma
    • Adenocarcinoma
      • Table 9: US Prevalence of Bladder Cancer by Type (includes corresponding Graph/Chart)
  • Major Risk Factors
    • Controllable Risk Factors
    • Uncontrollable Risk Factors
  • Symptoms and Diagnosis
    • Symptoms
    • Diagnosis
  • General Diagnostic Tests
    • Blood Tests
    • Physical Examination
    • Urine Test
  • Prescribed Procedure to Locate Bladder Cancer
    • Cytoscopy and Biopsy
    • Intravenous Pyelogram (IVP)
    • Ultrasound Scanning
  • Test/Procedures to Confirm Cancer Penetration
    • CT Scan
    • Radioisotope Bone Scan
  • Staging and Grading of Bladder Cancer: Crucial for Treatment
    • Staging
    • Grading

6. RESEARCH & DEVELOPMENT

  • Variations in PSCA Gene Increase Risk of Bladder Cancer
  • Genetic Analysis for Assaying Bladder Cancer Recurrence
  • Selenium Allays the Risk of Bladder Cancer
  • Individuals with Common Genome Variants at Increased Risk of Developing Bladder Cancer
  • New Studies Reveal Correlation Between Coffee and Bladder Cancer
  • Raw Cruciferous Vegetables Alleviates the Risk of Bladder Cancer
  • Broccoli Sprouts a Super-Food to Prevent Bladder Cancer
  • Well Water Counts to the Risk Factors for the Bladder cancer
  • Frankincense Oil: Potentially a Future Aid for Bladder Cancer
  • SRC Gene Suppresses Bladder Cancer Metastases

7. FDA APPROVALS AND FILINGS

  • Allos Therapeutics Obtains FDA Orphan Drug Designation for Pralatrexate
  • Aeterna Zentaris Secures FDA Approval for IND Application of AEZS-108
  • Biocancell Obtains FDA Clearance to Continue Clinical Trial for BC-819
  • Bioniche to Commence Additional Phase III Clinical Trial of Urocidin™
  • Bioniche Obtains FDA Approval for Phase III Trial of Urocidin
  • FDA Grants Fast Track Designation for Apaziquone (EOquin®)
  • Indevus Receives FDA Nod for Valstar
  • Biocancell Obtains FDA Approval of BC-819 for Phase IIb Clinical Trail

8. RECENT INDUSTRY ACTIVITY

  • MDRNA Takes Over Cequent Pharmaceuticals
  • MDRNA Changes Name to Marina Biotech
  • Telormedix Commences Phase I/II clinical Trial for TMX-101
  • Spectrum and Handok Ink Joint Marketing Agreement for Apaziquone in Korea
  • MDRNA Expands and Extends Collaboration with VPC
  • Endo Pharmaceuticals Acquires Indevus Pharmaceuticals
  • Affitech Merges with Pharmexa
  • Takeda America Holdings Acquires IDM Pharma
  • Schering-Plough Merges with Merck
  • Cell Genesys Merges with BioSante Pharmaceuticals
  • Celldex Therapeutics Acquires CuraGen
  • EMEA Grants Orphan Medicinal Product Designation for Pralatrexate
  • Endo Pharmaceuticals Obtains License for Urocidin
  • CHMP Issues Positive Opinion on JAVLOR® to Treat Metastatic Bladder Cancer
  • BioCis Pharma Initiates Phase I Clinical Trial of ProtoCure™
  • Sonus Pharmaceuticals Acquires OncoGenex Technologies
  • Callisto Merges with Celldex Therapeutics
  • Allergan and Spectrum Pharmaceuticals Collaborate for Apaziquone
  • Pro-Pharmaceuticals and BioCancell Collaborate to Administer siRNA for H19 Genes Destruction in Cancerous Cells
  • AVANT Adopts New Identity as Celldex Therapeutics
  • Lorus Therapeutics Receives New Patent for LOR-2040, Leukemia Drug
  • Spectrum Pharmaceuticals Obtains Canadian Authorities Approval for Phase III Clinical Trial of EOquin
  • NCCN Obtains Grant to Evaluate Cetuximab Efficacy in Bladder Cancer
  • Allos Therapeutics Commences Phase II Trials for Pralatrexate
  • Halozyme Announces Status Update of Chemophase® Phase I/IIa Clinical Trial
  • Spectrum Pharmaceuticals Establishes New Company in Canada
  • China Medical Technologies Acquires FISH Business
  • Peregrine Acquires Global License for Anti-Angiogenesis Technology
  • Bristol-Myers Terminates Partnership with Pierre Fabre

9. FOCUS ON SELECT GLOBAL PLAYERS

  • Affitech A/S (Denmark)
  • Allergan, Inc. (USA)
  • Allos Therapeutics, Inc. (USA)
  • Astellas Pharma, Inc. (Japan)
  • Astrazeneca Plc. (UK)
  • AVI BioPharma, Inc. (USA)
  • BioCancell Therapeutics, Inc. (Israel)
  • Bioniche Life Sciences, Inc. (Canada)
  • Bristol-Myers Squibb Company (USA)
  • Celldex Therapeutics, Inc. (USA)
  • Cytavis BioPharma GmbH (Germany)
  • Eli Lilly and Company (USA)
  • Endo Pharmaceuticals Holdings, Inc. (USA)
  • ENKAM Pharmaceuticals A/S (Denmark)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Halozyme Therapeutics, Inc. (USA)
  • Laboratoires Pierre Fabre SA (France)
  • NatImmune A/S (Denmark)
  • Oncogenex Pharmaceuticals, Inc. (USA)
  • OncoTherapy Science, Inc. (Japan)
  • Sanofi-Aventis (France)
  • Spectrum Pharmaceuticals, Inc. (USA)
  • Telormedix SA (Switzerland)
  • Viventia Biotechnologies, Inc. (Canada)

10. GLOBAL MARKET PERSPECTIVE

  • Table 10: World Recent Past, Current & Future Analysisfor Bladder Cancer Therapeutics by Geographic Region -US, Japan, Europe, and Rest of World MarketsIndependently Analyzed by Annual Revenuesin US$ Million for the Years 2007 through 2015(includes corresponding Graph/Chart)
  • Table 11: World Historic Review for Bladder Cancer Therapeutics by Geographic Region - US, Japan, Europe,and Rest of World Markets Independently Analyzed byAnnual Revenues in US$ Million for the Years 2001through 2006 (includes corresponding Graph/Chart)
  • Table 12: World 11-Year Perspective for Bladder Cancer Therapeutics by Geographic Region - Percentage Breakdownof Revenues for US, Japan, Europe, and Rest of WorldMarkets for the Years 2005, 2010 & 2015 (includescorresponding Graph/Chart)

III. MARKET

1. UNITED STATES

  • A. Market Analysis
    • Bladder Cancer & Prevalence - A Recapitulation of Facts
      • Mortality Rates Higher in African Americans
        • Table 13: Incidence of Bladder Cancer AmongAfrican Americans (Males): Percentage Share Breakdown by Select Cancer/Type or Site andGender for the Year 2007 (includescorresponding Graph/Chart)
    • Bladder Cancer - A Costly Urologic Condition
      • Table 14: Urologic Disease Costs in the US: 2006 (includes corresponding Graph/Chart)
    • US Bladder Cancer Statistics
      • Table 15: Bladder Cancer Prevalence and Mortality in the US by Gender: Percentage Share Breakdownfor 2009
      • Table 16: Bladder Cancer Incidence in the USby Gender: Percentage Share Breakdown for 2008
    • FDA Approval
    • Strategic Corporate Developments
    • Select Players
      • Allergan, Inc.
      • Allos Therapeutics, Inc.
      • AVI BioPharma, Inc.
      • Bristol-Myers Squibb Company
      • Celldex Therapeutics, Inc.
      • Eli Lilly and Company
      • Endo Pharmaceuticals Holdings, Inc.
      • Halozyme Therapeutics, Inc.
      • Marina Biotech, Inc.
      • Oncogenex Pharmaceuticals, Inc.
      • Peplin, Inc.
      • Polyphenon Pharma
      • Spectrum Pharmaceuticals, Inc.
  • B. Market Analytics
    • Table 17: US Recent Past, Current and Future Analysisfor Bladder Cancer Therapeutics - Annual Revenuesin US$ Million for the Years 2007 through 2015(includes corresponding Graph/Chart)
    • Table 18: US Historic Review for Bladder Cancer Therapeutics - Annual Revenues in US$ Millionfor the Years 2001 through 2006 (includescorresponding Graph/Chart)

2. JAPAN

  • A. Market Analysis
    • Current & Future Analysis
    • Select Players
      • alphaGEN, Co., Ltd
      • Astellas Pharma, Inc.
      • Nippon Kayaku Co., Ltd
      • OncoTherapy Science, Inc.
  • B. Market Analytics
    • Table 19: Japanese Recent Past, Current and FutureAnalysis for Bladder Cancer Therapeutics - AnnualRevenues in US$ Million for the Years 2007through 2015 (includes correspondingGraph/Chart)
    • Table 20: Japanese Historic Review for BladderCancer Therapeutics - Annual Revenues inUS$ Million for the Years 2001 through 2006(includes corresponding Graph/Chart)

3. EUROPE

  • A. Market Analysis
    • Current & Future Analysis
    • Bladder Cancer - Prevalence
      • Table 21: Bladder Cancer Incidence in Europe byRegion (2006) for Germany, Italy, Spain, France,The UK, Scandinavia, and Benelux (includescorresponding Graph/Chart)
      • Table 22: Bladder Cancer Mortality in Europe byRegion (2006) for Germany, Italy, the UK, Spain,France, Benelux, and Scandinavia (includescorresponding Graph/Chart)
    • Europe Lacks R&D Innovation in BladderCancer Market
    • Focus on Select Regional Market
      • United Kingdom
        • Bladder Cancer Prevalence - A Review
      • Bladder Cancer Statistics in the UK
        • Table 23: Incidence, Mortality, and Five-YearSurvival Rate of Bladder Cancer in UK byGender: 2006
        • Table 24: Bladder Cancer Incidence by Region(2006) for England, Wales, Scotland, andNorthern Ireland (includes correspondingGraph/Chart)
        • Table 25: Age-Specific Incidence of BladderCancer by Gender: 2006 (includescorresponding Graph/Chart)
        • Table 26: Number of Bladder Cancer Deaths inthe UK (2007): Breakdown by Region - England,Wales, Scotland, and Northern Ireland(includes corresponding Graph/Chart)
        • Table 27: Age-Specific Bladder Cancer MortalityRate in UK Males: Breakdown by Age Groupfor 2007 (includes corresponding Graph/Chart)
        • Table 28: Age-Specific Bladder Cancer MortalityRate in UK Females: Breakdown by Age Groupfor 2007 (includes corresponding Graph/Chart)
    • Strategic Corporate Developments
      • Select Players
      • Affitech A/S (Denmark)
      • Astrazeneca PLC (UK)
      • BioCis Pharma Ltd (Finland)
      • Cambridge Laboratories Ltd. (UK)
      • curasan AG (Germany)
      • Cytavis BioPharma GmbH (Germany)
      • ENKAM Pharmaceuticals A/S (Denmark)
      • F. Hoffmann-La Roche Ltd. (Switzerland)
      • Laboratoires Pierre Fabre SA (France)
      • NatImmune A/S (Denmark)
      • Sanofi-Aventis (France)
      • Telormedix SA (Switzerland)
  • B. Market Analytics
    • Table 29: European Recent Past, Current and Future Analysis for Bladder Cancer Therapeutics - AnnualRevenues in US$ Million for the Years 2007through 2015 (includes correspondingGraph/Chart)
    • Table 30: European Historic Review for BladderCancer Therapeutics - Annual Revenues inUS$ Million for the Years 2001 through 2006(includes corresponding Graph/Chart)

4. REST OF WORLD

  • A. Market Analysis
    • Current & Future Analysis
    • Select Markets
      • Canada
        • Bladder Cancer Treatment
        • Bladder Cancer Statistics
          • Table 31: Bladder Cancer New Cases in Canada: Percentage Share Breakdown by Gender for 2009
          • Table 32: Bladder Cancer Mortality in Canada: Percentage Share Breakdown by Genderfor 2009
          • Table 33: New Cases of Cancer AmongCanadian Females by Type: PercentageShare Breakdown for 2009 (includescorresponding Graph/Chart)
          • Table 34: Cancer Mortality Among CanadianFemales by Cancer Type: Percentage Share Breakdown for 2009 (includescorresponding Graph/Chart)
          • Table 35: New Cases of Cancer AmongCanadian Males by Type: Percentage Share Breakdown for 2009 (includescorresponding Graph/Chart)
          • Table 36: Cancer Mortality among CanadianMales by Cancer Type: Percentage ShareBreakdown for 2009 (includescorresponding Graph/Chart)
      • Asia-Pacific
        • China
        • India
        • Australia
          • Women at Increased Risk Over Men in Australia - A New Finding
            • Table 37: Number of Deaths Due to BladderCancer: Breakdown by Age Group forthe Year 2006 (includes correspondingGraph/Chart)
            • Table 38: Age-Standardized Mortality RateDue to Bladder Cancer in Australia:Breakdown by Age Group for the Year 2006 (includes corresponding Graph/Chart)
            • Table 39: Number of Deaths Due to BladderCancer (Males): Breakdown by Age Groupfor the Year 2006 (includes corresponding Graph/Chart)
            • Table 40: Number of Deaths Due to BladderCancer (Females): Breakdown by Age Groupfor the Year 2006 (includes corresponding Graph/Chart)
      • South Africa - Prevalence
    • FDA Approval
    • Strategic Corporate Developments
    • Select Players
      • BioCancell Therapeutics, Inc. (Israel)
      • Bioniche Life Sciences, Inc. (Canada)
      • China Medical Technologies Inc. (China)
      • Lorus Therapeutics, Inc. (Canada)
      • PharmaGap, Inc. (Canada)
      • Viventia Biotechnologies, Inc. (Canada)
  • B. Market Analytics
    • Table 41: Rest of World Recent Past, Current andFuture Analysis for Bladder Cancer Therapeutics -Annual Revenues in US$ Million for the Years 2007through 2015 (includes correspondingGraph/Chart)
    • Table 42: Rest of World Historic Review forBladder Cancer Therapeutics - Annual Revenuesin US$ Million for the Years 2001 through 2006(includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top